Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Mild Graves' Orbitopathy
NCT05126147Phase 4Active, not recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of hydroxychloroquine in Graves' ophthalmopathy (TED), sponsored by National Taiwan University Hospital. Started Mar 2022; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT05126147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126147.